Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Statistics in Medicine|January 3, 2008
Parametric models for spatially correlated survival data for individuals with multiple cancersUlysses Diva, Dipak K Dey, Sudipto BanerjeeStatistical Modelling|October 1, 2009
Modelling spatially correlated survival data for individuals with multiple cancersUlysses Diva, Sudipto Banerjee, Dipak K DeyPain Practice : the Official Journal of World Institute of Pain|September 13, 2017
Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced ConstipationLynn Webster, Ulysses Diva, Raj Tummala, et al.Clinical Pharmacology in Drug Development|January 28, 2017
An Open-Label, Randomized Bioavailability Study of Alternative Methods of Oral Administration of Naloxegol in Healthy SubjectsKhanh Bui, Bruce Birmingham, Ulysses Diva, et al.Journal of Opioid Management|January 7, 2017
A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipationLynn Webster, Raj Tummala, Ulysses Diva, et al.Connecticut Medicine|May 29, 2007
A population based survey of ergonomic risk factors in Connecticut: distribution by industry, occupation, and demographicsTim F Morse, Nicholas Warren, Charles Dillon, et al.United European Gastroenterology Journal|November 5, 2015
Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate responseJan Tack, Jaakko Lappalainen, Ulysses Diva, et al.Journal of Cardiovascular Pharmacology and Therapeutics|March 6, 2018
Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced ConstipationWilliam B White, Peter Kowey, Ulysses Diva, et al.Kidney International Reports|October 18, 2023
Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET TrialHoward Trachtman, Ulysses Diva, Edward Murphy, et al.Kidney International Reports|April 11, 2020
Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental GlomerulosclerosisRadko Komers, Ulysses Diva, Jula K Inrig, et al.Pageof 2